You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for oxfendazole


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for oxfendazole?

oxfendazole is an investigational drug.

There have been 7 clinical trials for oxfendazole. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2022.

The most common disease conditions in clinical trials are Trichuriasis, Helminthiasis, and Taeniasis. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Universidad Peruana Cayetano Heredia, and Johns Hopkins Bloomberg School of Public Health.

There are three hundred and sixty-three US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for oxfendazole
TitleSponsorPhase
Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in AdultsUniversidad Peruana Cayetano Heredia, Lima, PeruPhase 2
Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in AdultsOxfendazole Development GroupPhase 2
PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole TabletsDrugs for Neglected DiseasesPhase 1

See all oxfendazole clinical trials

Clinical Trial Summary for oxfendazole

Top disease conditions for oxfendazole
trials0112233TrichuriasisHelminthiasisTaeniasisNeurocysticercosis[disabled in preview]
Top clinical trial sponsors for oxfendazole
trials0112233National Institute of Allergy and Infectious Diseases (NIAID)Universidad Peruana Cayetano HerediaJohns Hopkins Bloomberg School of Public Health[disabled in preview]

See all oxfendazole clinical trials

US Patents for oxfendazole

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
oxfendazole ⤷  Subscribe Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Subscribe
oxfendazole ⤷  Subscribe Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ) ⤷  Subscribe
oxfendazole ⤷  Subscribe Fast dissolving pharmaceutical composition Ferring B.V. (Hoofddorp, NL) ⤷  Subscribe
oxfendazole ⤷  Subscribe Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same Platform Brightworks Two, Ltd. (Houston, TX) ⤷  Subscribe
oxfendazole ⤷  Subscribe Six-membered C--N-bonded aryl sulphide and aryl sulphoxide derivatives as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) ⤷  Subscribe
oxfendazole ⤷  Subscribe Anthelmintic compounds MERIAL INC. (Duluth, GA) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 6 of 6 entries

International Patents for oxfendazole

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
oxfendazole Australia AU2015286634 2034-07-11 ⤷  Subscribe
oxfendazole Brazil BR112017000398 2034-07-11 ⤷  Subscribe
oxfendazole China CN106659720 2034-07-11 ⤷  Subscribe
oxfendazole European Patent Office EP2981556 2033-04-02 ⤷  Subscribe
oxfendazole European Patent Office EP3177291 2034-07-11 ⤷  Subscribe
oxfendazole World Intellectual Property Organization (WIPO) WO2014165513 2033-04-02 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 6 of 6 entries

Oxfendazole: A Promising Drug Candidate for Parasitic Infections

Introduction

Oxfendazole, a veterinary antiparasitic drug, is being vigorously developed for human use to treat various parasitic infections, including those caused by filarial and helminth parasites. This article provides an update on the current development stage of oxfendazole and projects its market potential.

Background and Pre-Clinical Development

Oxfendazole was initially identified through the screening of drug libraries and literature reviews as a potential macrofilaricidal treatment for parasitic infections such as river blindness and onchocerciasis. Pre-clinical data have shown highly encouraging results on its efficacy against filarial nematodes, including Litomosoides sigmodontis and Onchocerca species[1][4].

Clinical Development Updates

Phase I Trials

The clinical development of oxfendazole has progressed significantly. Phase I trials, conducted by the Swiss Tropical and Public Health Institute (Swiss TPH) and the Ifakara Health Institute in Tanzania, have demonstrated the safety and bioavailability of a field-adapted oxfendazole tablet. These trials showed no serious adverse events and confirmed that oxfendazole is safe and well-tolerated in humans at various doses[1].

Phase II Trials

Following the successful Phase I trials, the Oxfendazole Development Group has initiated a Phase II clinical trial to evaluate the safety and efficacy of oxfendazole in patients infected with Trichuris trichiura, a parasitic whipworm. This trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID), is being conducted in the Amazonian region of Peru and involves a comparison of oxfendazole with the current standard treatment, albendazole[4].

eWHORM and HELP Consortium

The eWHORM consortium, launched in 2023, is a collaborative effort between research institutes, universities, and not-for-profit organizations aimed at establishing an adaptive clinical trial platform for various soil-transmitted helminths and filarial worms. This initiative is designed to expedite drug development, improve trial efficiency, and optimize resource utilization, ultimately speeding up access to improved treatments for patients[1].

Safety and Efficacy Profile

Oxfendazole has shown a promising safety and efficacy profile in both pre-clinical and clinical studies. The drug has been found to achieve higher plasma levels than some currently approved medicines, suggesting it could be more efficacious against human worm infections. The Phase I studies in healthy volunteers confirmed its safety and tolerability at doses up to 60 mg/kg and repeated daily doses of up to 15 mg/kg[1][4].

Market Projections

Global Market Size and Growth

The global oxfendazole market is expected to grow at a compound annual growth rate (CAGR) of 3 to 5 percent from 2024 to 2031. This growth is driven by the increasing need for effective treatments against neglected tropical diseases (NTDs) such as trichuriasis and filarial infections[2][5].

Market Drivers

The market growth for oxfendazole is driven by several factors:

  • Increasing Prevalence of NTDs: Parasitic infections like trichuriasis and filarial diseases affect millions worldwide, particularly in under-resourced areas.
  • Need for Effective Treatments: Current treatments often have limitations in terms of efficacy and safety, making oxfendazole a promising alternative.
  • Collaborative Efforts: Initiatives like the eWHORM consortium and the HELP Consortium are accelerating the development and clinical evaluation of oxfendazole[1][4].

Challenges and Opportunities

Regulatory Approvals

Obtaining regulatory approvals is a critical step in the development process. The successful acquisition of regulatory approvals for the Phase I study in Tanzania sets a positive precedent for future trials[1].

Funding and Partnerships

The development of oxfendazole is supported by significant funding from organizations such as the European Union’s Horizon 2020 research and innovation programme and the NIAID. Partnerships with non-profit organizations, universities, and research institutes are also crucial for advancing the clinical program[1][4].

Key Takeaways

  • Oxfendazole is being developed as a treatment for various parasitic infections, including filarial and helminth diseases.
  • Phase I trials have demonstrated the safety and bioavailability of oxfendazole in humans.
  • Phase II trials are underway to evaluate its efficacy against Trichuris trichiura.
  • Market growth is expected due to the increasing need for effective treatments against NTDs.
  • Collaborative efforts and significant funding are driving the development process.

FAQs

What is oxfendazole?

Oxfendazole is a veterinary antiparasitic drug being developed for human use to treat parasitic infections such as river blindness and trichuriasis.

What is the current stage of oxfendazole's clinical development?

Oxfendazole has completed Phase I trials and is currently in Phase II trials to evaluate its safety and efficacy against Trichuris trichiura.

How safe is oxfendazole?

Phase I trials have shown that oxfendazole is safe and well-tolerated in humans at various doses, with no serious adverse events reported.

What are the market projections for oxfendazole?

The global oxfendazole market is expected to grow at a CAGR of 3 to 5 percent from 2024 to 2031.

Who are the key partners in the development of oxfendazole?

Key partners include the Swiss Tropical and Public Health Institute, the Ifakara Health Institute, the Oxfendazole Development Group, and various non-profit organizations and universities.

Sources

  1. DNDi: Oxfendazole | DNDi
  2. Market Research Intellect: Global oxfendazole market size and forecast
  3. ResearchGate: Prediction-corrected visual predictive check for oxfendazole
  4. Oxfendazole Development Group: Oxfendazole Development Group Announces Enrollment of First Patient in Phase 2 Trial of Oxfendazole for Trichuris trichiura Infection
  5. Cognitive Market Research: Global Oxfendazole Market Report 2024 Edition, Market Size, Share ...

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.